J&J Hits Another Myeloma Milestone With FDA Approval Of Talvey

First Approved GPRC5D-Directed Therapy

 
• By Alaric DeArment
J&J got another first in myeloma, this time with the approval of a GPRC5D-directed bispecific antibody • Source: Shutterstock

More from New Products

More from Scrip